Changjiang Securities·2025-09-01 14:42Investment Rating - The report maintains a "Buy" rating for China Life Insurance [2][8]. Core Views - The report suggests that with the increase in equity allocation, the long-term interest spread in the industry is expected to improve. The demand on the liability side remains robust, and the market is concentrated, indicating a positive outlook for the industry's long-term profitability and valuation re-evaluation. In the short term, the asset side presents the main challenges for the industry. As a pure life insurance company, China Life is positioned in the first tier of the industry in terms of sensitivity and elasticity, making it a quality beta asset for allocation. The current valuation stands at 0.78 times PEV [2][12]. Summary by Sections Financial Performance - In the first half of 2025, China Life achieved a net profit attributable to shareholders of 40.93 billion yuan, representing a year-on-year increase of 6.9%. The comparable new business value was 28.55 billion yuan, up 20.3% year-on-year [6][12]. Investment Strategy - The company has increased its equity allocation by 1.12 percentage points to 8.7% and its fund allocation by 0.28 percentage points to 4.92%, reflecting a commitment to long-term capital market responsibilities [12]. New Business Growth - The new business value for the first half of 2025 was 28.55 billion yuan, with a year-on-year growth of 20.3%. The improvement in value rate was a significant factor, with new single premiums slightly increasing by 0.6% year-on-year [12]. Individual Insurance and Bancassurance - The individual insurance long-term new single premium was 64.25 billion yuan, down 24.2% year-on-year, primarily due to the transformation of dividend insurance. The bancassurance long-term new single premium reached 35.67 billion yuan, a strong increase of 112.4% year-on-year, indicating a significant trend of "deposit migration" [12].